Wegovy Pill Sales Beat Forecasts. Novo's Profit Story Is More Complicated.

Novo Nordisk’s oral Wegovy product generated 5.394 billion Danish kroner in third-quarter 2026 sales, giving the Danish drugmaker a much-needed growth signal in a fiercely competitive obesity-treatment market. The number exceeded analysts' sales expectations, and Novo raised its full-year adjusted outlook. But the headline is easy to misread: adjusted operating profit rose sharply while reported operating profit fell. The difference is more than an accounting footnote.

Novo's November 4 quarterly release shows DKK 5.394 billion in Wegovy pill revenue, DKK 31.720 billion in adjusted operating profit and DKK 23.011 billion in reported operating profit.

Why the pill result mattered

Wegovy's oral formulation gives the company a commercial product that does not depend on injection. For investors, the important question is whether the pill expands the market and helps Novo compete against rival treatments. Reuters reported sales 53% above the previous quarter and ahead of company-compiled consensus of DKK 4.62 billion. Those figures measure product revenue; they do not by themselves measure long-term patient outcomes or adherence.

Novo said the pill was launched in the United States, United Arab Emirates, United Kingdom and Germany by the end of the quarter. Geographic launches and commercial uptake can broaden the addressable market, although pricing, reimbursement, supply, patient preferences and competitors will determine whether momentum lasts. A strong first year of sales is not the same as durable dominance.

Adjusted profit rose; reported profit fell

The company reported third-quarter adjusted operating profit growth of 27% at constant exchange rates, to DKK 31.720 billion. Its reported operating profit, however, decreased 9% at constant exchange rates, to DKK 23.011 billion. Novo attributed part of the discrepancy to DKK 8.7 billion of non-cash impairments related to ziltivekimab and manufacturing-network adjustments. Saying simply that profit 'surged 27%' omits the decline in the reported measure.

The detailed financial report distributed via Nasdaq distinguishes the adjusted and reported figures and gives the impairment context.

A brighter forecast with meaningful limits

Novo now expects both adjusted sales growth and adjusted operating-profit growth between -2% and +2% at constant exchange rates for 2026. The midpoint is around zero growth; the new range is better than its previous expectations but not a promise of expansion. The outlook depends on continued GLP-1 demand and on the same volatile commercial dynamics that affected earlier quarters.

The company still faces a strong competitor in Eli Lilly. Market share depends on overall treatment choices, commercial contracts and regional approvals, while the two companies may compete on convenience, supply and economics. Any analyst consensus or market-share metric should be dated and attributed rather than presented as a permanent lead.

Reuters reported the raised guidance and analyst comparison, including why an oral product was closely watched in competition with Lilly.

What investors and readers should watch next

The next useful measures are sequential oral-product sales, changes in injectable demand, reimbursement reach, manufacturing capacity and profit conversion as the launch matures. Strong sales can coexist with charges, spending and changes to future guidance. A quarter that beats forecasts improves the company's position without settling the next years of competition.

This is a business-performance story, not a guide to choosing a medicine. Approval status, medical suitability, side effects and patient treatment are separate questions best addressed through official prescribing information and a qualified clinician. The supported conclusion is narrower and significant: Novo found commercial traction with the pill and improved its adjusted outlook, while reported profitability still shows the costs and risks of transformation.